A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
About the study
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Key Inclusion Criteria:
- Able to understand the study requirements and provide written informed consent before any study assessment is performed
- Male or female patients ≥ 18 to 65 years of age
- Recipient of a renal transplant from a non-human leukocyte antigen (HLA)-identical but at least haploidentical, ABO compatible living donor
EXCLUSION CRITERIA
Key Exclusion Criteria:
- Women of child-bearing potential, unless willing to comply with the use of highly effective methods of contraception as defined by the protocol
- A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
- Recipient with anti-HLA donor-specific antibody (DSA)
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Kidney Transplantation
Age (in years)
18 - 65
Phase
PHASE2
Participants needed
18
Est. Completion Date
Mar 31, 2030
Treatment type
INTERVENTIONAL
Sponsor
ITB-Med LLC
ClinicalTrials.gov identifier
NCT04803058
Study number
TCD601A202
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?